Actimed Therapeutics
Clinical-stage drug developer targeting cancer cachexia and muscle wasting with S-pindolol benzoate in Phase 2
Highlights
- New on EvolcAdded 2026-10-31
About Actimed Therapeutics
Actimed Therapeutics develops drugs for cachexia and other muscle wasting conditions. Its lead candidate, S-pindolol benzoate (ACM-001.1), a new salt of S-pindolol, is in clinical development for cancer-related cachexia and for muscle wasting associated with GLP-1 receptor agonist therapy. The pipeline also includes S-oxprenolol (ACM-002), whose global rights the company reacquired in 2026.
The company targets patients with cancer-related cachexia and patients losing lean muscle mass during weight-loss treatment with GLP-1 receptor agonists. A Phase 2a proof-of-concept trial of S-pindolol in cancer cachexia reported promising results, and a Phase 2b/3 programme (IMPACT) is planned in non-small cell lung and colorectal cancers. A Phase 2a study in obese adults during and after semaglutide therapy completed recruitment in September 2026.
Actimed was founded in 2016 and is headquartered in Ascot, United Kingdom. A US Investigational Drug Application for S-pindolol and the IMPACT studies has received FDA approval. The company was co-founded by Professors Andrew Coats and Stefan Anker, both cachexia researchers, and is led by a management team and board.
Product: Investigational drugs S-pindolol benzoate (ACM-001.1) and S-oxprenolol (ACM-002) for cachexia and muscle wasting.
Jobs at Actimed Therapeutics
Leadership
- Andrew J. Stewart Coats · Founder and Non-Executive DirectorSource: company website
- Stefan D. Anker · Founder, Non-executive Director & Chair of Scientific Advisory BoardSource: company website
- Yann Colardelle · FounderSource: company website
More biotech & pharma companies
Ads Biotec
Automated laboratory instruments, consumables and purification solutions for cytogenetic, pathology and research labsNew on EvolcAixcell
Autonomous cell culture system running routine and multi-project cell-based workflows for AI/ML data generationNew on EvolcAlimera Sciences
Develops and commercialises ophthalmic medicines for patients with chronic retinal diseasesNew on EvolcAmphista Therapeutics
Develops Targeted Glue protein-degrader medicines for cancer, with a lead acute myeloid leukemia candidate in Phase 1New on EvolcAnanda Pharma
Develops cannabinoid-based medicines for inflammatory pain conditions and heart failureNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Bootstrap
- Cloudflare
- Google Universal Analytics
- jQuery